Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191329 | 0.89 | MEN1 (0.45) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL20400477 | 0.84 | P2RX3 (0.37) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL4191240 | 0.82 | NPC1 (0.39) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL20565389 | 0.81 | MEN1 (0.43) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL4186947 | 0.79 | KMT2A (0.38) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL29001335 | 0.78 | KMT2A (0.39) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL20382691 | 0.78 | SMYD3 (0.38) | MEN1KMT2ASMYD3ALDH1A1 | |
| SCHEMBL15149903 | 0.77 | NPC1 (0.41) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL5824115 | 0.76 | NPC1 (0.41) | NPC1RAB9AP2RX3MEN1KMT2A | |
| SCHEMBL4181795 | 0.76 | MEN1 (0.45) | NPC1RAB9AP2RX3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | NPC1 412/4885RAB9A 1644/4885P2RX3 560/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | NPC1 1911/4885RAB9A 1303/4885P2RX3 929/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | NPC1 412/4885RAB9A 1644/4885P2RX3 560/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | NPC1 412/4885RAB9A 1644/4885P2RX3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.